Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $28.20.

ELAN has been the topic of a number of recent analyst reports. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. KeyCorp upped their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Morgan Stanley upped their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Finally, UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th.

Elanco Animal Health Trading Down 0.5%

NYSE:ELAN opened at $23.86 on Monday. The firm has a market cap of $11.92 billion, a P/E ratio of -47.72, a PEG ratio of 2.58 and a beta of 1.69. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The stock’s 50 day simple moving average is $22.96 and its 200-day simple moving average is $23.32. Elanco Animal Health has a 12-month low of $13.09 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities analysts anticipate that Elanco Animal Health will post 1.11 EPS for the current year.

Insiders Place Their Bets

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of institutional investors have recently bought and sold shares of ELAN. UBS Group AG boosted its position in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares in the last quarter. Sei Investments Co. boosted its position in Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after purchasing an additional 4,975,721 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares in the last quarter. Invesco Ltd. boosted its position in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after purchasing an additional 3,690,735 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Elanco Animal Health during the first quarter worth $66,390,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.